Featured: Trading Tips

[Suspension].

688038 Zhongke Tongda

603776 Yong'an Xing

[Resumption].

688126 Shanghai silicon industry

600539 Lion Head shares

002656 ST Modern (Rights Protection).

[Product].

2. Lianban Yunnei Power (Rights Protection): The company's unmanned delivery vehicles are still in the road test stage

Yunnei Power announced that the company's shares will have a cumulative deviation of 20.60% from the closing price of the company's shares for three consecutive trading days from March 5 to 7, 2025, which is an abnormal fluctuation in stock trading. There is no substantial progress in the fuel cell power generation system contract between the company and CCCC Electromechanical, and the installation and commissioning of the production line of the rubber tapper project has been basically completed. The Kunming Municipal Government has issued a road test license for intelligent networked vehicles to the company, and is currently carrying out road tests of unmanned delivery vehicles with China Post Yunnan Branch. In addition to the above matters, the company has no material matters that should be disclosed but have not been disclosed. At present, the company's unmanned delivery vehicle is still in the road test stage, and there are still uncertainties about whether it can be industrialized, and there are still uncertainties about whether the intelligent rubber tapper can be commercialized on a large scale in the future.

Mingke Precision: The company provides mold process and parts production support for Wenjie M8

Mingke Jingji announced that in the near future, the company's long-term strategic customer Cialis will soon release and promote its new model "Wenjie M8", which has attracted high market attention. The company provided tooling process and parts production support for the project, and has started the production and delivery of prototypes in June 2024, and is expected to enter the mass production stage with the launch of the model in the near future. The life cycle of the project is expected to be three years, and the new output value during the period is expected to be 3.1-630 million yuan, but the actual mass production time and output value growth are still affected by the launch progress of the model and the terminal sales. At present, the project is still in the prototype delivery stage, and its contribution to the company's full-year 2025 operating results is temporarily limited.

Guomai Technology: The technical achievements related to AI agents have not yet formed commercial revenue

Guomai Technology announced that the company has noticed that some media have listed the company as the core leading stock of AI Agent. Based on the technology accumulation in the field of body networking and smart health care, the company has completed the prototype development of AI agent (AI agent) for some home-based elderly care scenarios, and the product is currently in the stage of scene adaptation optimization and user experience improvement, and the related technical achievements have not yet formed commercial income, which will not have a significant impact on the company's operating performance in the short term.

Chifeng Gold: H shares will be listed and traded on March 10

Chifeng Gold announced that with the approval of the Hong Kong Stock Exchange, the 206 million H shares issued by the company (before exercising the over-allotment option) will be listed and traded on the main board of the Hong Kong Stock Exchange on March 10, 2025. The company's H-share stock is abbreviated as "Chifeng Gold" in Chinese, and the stock code is "06693".

Hengrui Pharmaceutical: HRS-4029 for injection was approved for clinical trial

Hengrui Pharmaceutical announced that the company's subsidiaries Fujian Shengdi Pharmaceutical Co., Ltd. and Beijing Shengdi Pharmaceutical Co., Ltd. recently received the approval of the State Food and Drug Administration to issue the "Drug Clinical Trial Approval Notice" on HRS-4029 for injection, and will carry out clinical trials in the near future. HRS-4029 for injection is a novel neuroprotective agent that can attenuate excitoneurotoxicity and is intended for the treatment of acute ischemic stroke.

Huana Pharmaceutical: It is planned to invest no more than 500 million yuan in the construction of a green intelligent manufacturing base (phase II) project with an annual output of 3,000 tons of high-end APIs and intermediates

Huana Pharmaceutical announced that the company intends to build a "green intelligent manufacturing base (phase II) construction project with an annual output of 3,000 tons of high-end APIs and intermediates" with a wholly-owned grandson company, Hunan Huana Pharmaceutical Factory Zhigen Pharmaceutical Co., Ltd., with an estimated total investment of no more than 500 million yuan.

[Performance].

Huaming Equipment Performance Express: Net profit in 2024 will be 614 million yuan, a year-on-year increase of 13.17

Huaming Equipment released a performance report, achieving a total operating income of 2.324 billion yuan in 2024, a year-on-year increase of 18.51%; net profit was 614 million yuan, a year-on-year increase of 13.17%; Basic earnings per share was 0.68 yuan.

Changlian performance express: net profit of 131 million yuan in 2024 decreased by 14.51% year-on-year

Changlian Co., Ltd. released a performance report, achieving a total operating income of 1.52 billion yuan in 2024, a year-on-year decrease of 6.89%; net profit was 131 million yuan, down 14.51% year-on-year; Basic earnings per share was 0.36 yuan.

Zuoli Pharmaceutical: Net profit in the first quarter increased by 24.99%-32.71% year-on-year The chairman proposed 10 distributions of 6 yuan in 2024

Zuoli Pharmaceutical released a performance forecast, which is expected to be 178 million yuan to 189 million yuan in the first quarter of 2025, a year-on-year increase of 24.99%-32.71%. Zuoli Pharmaceutical announced on the same day that Yu Youqiang, the company's controlling shareholder, actual controller and chairman, proposed that the company implement the 2024 equity distribution plan in the future, distribute cash dividends of 6 yuan (tax included) to all shareholders for every 10 shares, and do not give bonus shares, nor convert capital reserve to share capital.

[Increase or decrease in holdings].

Kangpeng Technology: Shareholders are expected to reduce their holdings of no more than 6% of the company's shares in total

Kangpeng Technology announced that shareholders Wuxi Yunhui, Xingyu Huitian, Tongxiang Jiawo, Tongxiang Yunhui and Tongxiang Bifang plan to reduce their holdings of the company's shares by a total of no more than 31,162,500 shares (accounting for 6% of the company's total share capital) through centralized bidding and block trading.

Changchun Yidong: FAW Equity Company plans to reduce its holdings of no more than 3% of the company's shares

Changchun Yidong announced that FAW Equity Investment (Tianjin) Co., Ltd. (hereinafter referred to as "FAW Equity Company"), a 22.52% shareholder, intends to reduce its total holdings of the company's shares by centralized bidding transactions and block transactions not exceeding 4,245,500 shares, that is, no more than 3% of the company's total share capital.

Yiming Pharmaceutical: Directors and shareholders will reduce their holdings of no more than 2.04% of the company's shares in total

Yiming Pharmaceutical announced that Zhou Zhan, the company's directors and shareholders holding more than 5% of the shares, plans to reduce the company's shares by centralized bidding or block trading no more than 3.59 million shares (no more than 1.8828% of the company's total share capital) within 3 months after 15 trading days; Within 3 months after 15 trading days, the directors' license plan will reduce the company's shares by centralized auction or block trading by no more than 300,000 shares (no more than 0.1573% of the company's total share capital).

[Do a repurchase].

Lanzhou Yellow River: plans to repurchase shares for 20 million yuan - 30 million yuan

Lanzhou Yellow River announced that the company intends to repurchase shares with 20 million yuan to 30 million yuan for equity incentives or employee stock ownership plans. The repurchase price does not exceed 9.7 yuan per share.

[Refinancing].

Baili Tianheng: It is planned to raise no more than 3.9 billion yuan for innovative drug research and development projects

Baili Tianheng announced that the company intends to issue shares to specific objects to raise no more than 3.9 billion yuan, which will be used for innovative drug research and development projects after deducting the issuance costs.